- July 2010, Joint Press Release
reMYND and Amorfix announce agreement
reMYND en Amorfix kondigen overeenkomst aan
- June 2010, Joint Press Release
Ablynx and reMYND settle dispute amicably
Ablynx en reMYND treffen minnelijke schikking
- January 2010, In The Press
The case Alzheimer (in Dutch)
- December 2009
reMYND receives a grant of 0.9 million EUR from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT)
- November 2009, Press Release
reMYND receives license renewal from Schering-Plough for RadarScreen
- October 2009, In The Press
reMYND tackles dementia with innovation (VOKA brochure Kennisregio Vlaams-Brabant in Dutch)
- September 2009, In The Press
On September 21st 2009, reMYND received in the Flemish Parliament 'the 1st Award for Company with an exceptional relevance to society' out of the hands of the Flemish minister-president Kris Peeters.
- July 2009
reMYND is one of the nine biotech and pharmaceutical companies that have been awarded by the Michael J. Fox Foundation for Parkinson's Research in July 2009
- January 2009
reMYND signs a license with BioPredic for commercialization RadarScreen as a diagnostic kit for experimental use in Europe and Japan
- December 2008
reMYND receives a grant of almost 1 million EUR from the Institute for the Promotion of Innovation by Science and Technology in Flanders
- November 2008
reMYND’s Lead Alzheimer drug demonstrates neuroprotection in 2 transgenic animal models of TAU and Amyloid bèta pathology
- October 2008
reMYND grants non-exclusive license of RadarScreen technology to Top 20 pharma-company
- August 2008
reMYND licenses highly innovative transgenic mouse models of Alzheimer’s Disease’ TAU and Amyloid pathology from the University of Leuven
- June 2008
reMYND installs world-class scientific advisory board with Parkinson’s and Alzheimer’s Disease experts
- March 2008
Lead product for treating Parkinson’s Disease
demonstrates efficacy in 3 different animal models of Parkinson’s Disease: a chemically-induced model and 2 different transgenic α-synuclein mouse models
- December 2007
reMYND signs a license agreement with another biotech company for their internal use of reMYND’s proprietary APPLon model
- Press Release : 26/03/2007
reMYNDs Parkinsons disease drug discovery program reaches breakthrough
